JPWO2022221697A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022221697A5 JPWO2022221697A5 JP2023563210A JP2023563210A JPWO2022221697A5 JP WO2022221697 A5 JPWO2022221697 A5 JP WO2022221697A5 JP 2023563210 A JP2023563210 A JP 2023563210A JP 2023563210 A JP2023563210 A JP 2023563210A JP WO2022221697 A5 JPWO2022221697 A5 JP WO2022221697A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- mol
- amount
- lnp composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176227P | 2021-04-17 | 2021-04-17 | |
| US63/176,227 | 2021-04-17 | ||
| US202163254948P | 2021-10-12 | 2021-10-12 | |
| US63/254,948 | 2021-10-12 | ||
| US202163274153P | 2021-11-01 | 2021-11-01 | |
| US63/274,153 | 2021-11-01 | ||
| US202263316568P | 2022-03-04 | 2022-03-04 | |
| US63/316,568 | 2022-03-04 | ||
| PCT/US2022/025076 WO2022221697A1 (en) | 2021-04-17 | 2022-04-15 | Lipid nanoparticle compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515650A JP2024515650A (ja) | 2024-04-10 |
| JP2024515650A5 JP2024515650A5 (https=) | 2025-04-21 |
| JPWO2022221697A5 true JPWO2022221697A5 (https=) | 2025-04-21 |
Family
ID=81580499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563210A Pending JP2024515650A (ja) | 2021-04-17 | 2022-04-15 | 脂質ナノ粒子組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250090471A1 (https=) |
| EP (1) | EP4322920A1 (https=) |
| JP (1) | JP2024515650A (https=) |
| KR (1) | KR20240017792A (https=) |
| AU (1) | AU2022257050A1 (https=) |
| BR (1) | BR112023021477A2 (https=) |
| CA (1) | CA3216877A1 (https=) |
| CL (1) | CL2023003077A1 (https=) |
| CO (1) | CO2023015485A2 (https=) |
| CR (1) | CR20230536A (https=) |
| IL (1) | IL307738A (https=) |
| MX (1) | MX2023012235A (https=) |
| TW (1) | TW202308597A (https=) |
| WO (1) | WO2022221697A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3234127A1 (en) * | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| WO2024138189A2 (en) | 2022-12-22 | 2024-06-27 | Intellia Therapeutics, Inc. | Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies |
| WO2024199282A1 (zh) * | 2023-03-28 | 2024-10-03 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025064396A1 (en) | 2023-09-18 | 2025-03-27 | Intellia Therapeutics, Inc. | Nuclease resistant double stranded dna product for non-viral delivery to a cell and methods of production thereof |
| WO2025064401A1 (en) | 2023-09-18 | 2025-03-27 | Intellia Therapeutics, Inc. | Nuclease resistant single stranded dna product for non-viral delivery to a cell and methods of production thereof |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) * | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| WO2025240946A1 (en) | 2024-05-17 | 2025-11-20 | Intellia Therapeutics, Inc. | Lipid nanoparticles and lipid nanoparticle compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| WO2011091324A2 (en) | 2010-01-22 | 2011-07-28 | The Scripps Research Institute | Methods of generating zinc finger nucleases having altered activity |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| AU2020248337A1 (en) * | 2019-03-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| US12569438B2 (en) * | 2019-07-29 | 2026-03-10 | Georgia Tech Research Corporation | Nanomaterials containing constrained lipids and uses thereof |
-
2022
- 2022-04-15 BR BR112023021477A patent/BR112023021477A2/pt not_active Application Discontinuation
- 2022-04-15 TW TW111114501A patent/TW202308597A/zh unknown
- 2022-04-15 IL IL307738A patent/IL307738A/en unknown
- 2022-04-15 KR KR1020237039429A patent/KR20240017792A/ko active Pending
- 2022-04-15 JP JP2023563210A patent/JP2024515650A/ja active Pending
- 2022-04-15 AU AU2022257050A patent/AU2022257050A1/en active Pending
- 2022-04-15 EP EP22721589.4A patent/EP4322920A1/en active Pending
- 2022-04-15 CR CR20230536A patent/CR20230536A/es unknown
- 2022-04-15 CA CA3216877A patent/CA3216877A1/en active Pending
- 2022-04-15 MX MX2023012235A patent/MX2023012235A/es unknown
- 2022-04-15 US US18/287,239 patent/US20250090471A1/en active Pending
- 2022-04-15 WO PCT/US2022/025076 patent/WO2022221697A1/en not_active Ceased
-
2023
- 2023-10-16 CL CL2023003077A patent/CL2023003077A1/es unknown
- 2023-11-16 CO CONC2023/0015485A patent/CO2023015485A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI271407B (en) | Methods and compositions for treating inflammatory response | |
| Look et al. | Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice | |
| JPWO2022221697A5 (https=) | ||
| AU2016331084B2 (en) | Compositions and methods for inhibiting gene expression of LPA | |
| Mutis et al. | Feasibility of immunotherapy of relapsed leukemia with ex vivo–generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens | |
| JPWO2020072605A5 (https=) | ||
| Ludewig et al. | Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells | |
| JP2012526134A5 (https=) | ||
| EP4615476A2 (en) | Preparation of lipid nanoparticle (lnp) conjugates | |
| JPH04505752A (ja) | オリゴヌクレオチドを使用する癌治療用の方法及び組成物 | |
| EP1469009A2 (en) | Compositions and methods for non-parenteral delivery of oligonucleotides | |
| JPWO2020118041A5 (https=) | ||
| HUE025782T2 (en) | 5-Aza-cytosine-containing oligonucleotide analogs | |
| JPWO2021222287A5 (https=) | ||
| JP7795356B2 (ja) | 細胞調節剤の送達のためのナノカプセル | |
| JP2025535815A (ja) | 脂質組成物および治療剤を送達する方法 | |
| EP4132461A1 (en) | Oxidized tumor cell lysates encapsulated in liposomal spherical nucleic acids as potent cancer immunotherapeutics | |
| JP2018197274A (ja) | 初発自己免疫性糖尿病を予防するため、および／または逆転させるためのマイクロスフェアに基づく組成物 | |
| Li et al. | Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses | |
| TW202120104A (zh) | 用於治療apoc3相關疾病及病症之方法 | |
| Kim et al. | Strategy to Enhance Dendritic Cell‐Mediated DNA Vaccination in the Lung | |
| JP2013526519A (ja) | アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法 | |
| MX2025005209A (es) | Compuestos lipídicos y usos de los mismos | |
| AU2023375377A1 (en) | Lipid nanoparticle drug conjugates | |
| EP1771548B1 (fr) | Utilisation de dendrimeres pour stimuler la croissance cellulaire |